MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND
The presentation entitled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (ibudilast) in ALS: Trial Update was given by Malath Makhay, Ph.D., Director, Scientific Affairs, MediciNova, Inc. during the live poster session.
- The presentation entitled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (ibudilast) in ALS: Trial Update was given by Malath Makhay, Ph.D., Director, Scientific Affairs, MediciNova, Inc. during the live poster session.
- In this poster presentation, Dr. Makhay discussed the study objectives, scientific rationale, study design, and demographic and baseline characteristics of the study participants as of August 2021.
- Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
- MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.